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resumo 
 
 
A relação entre o número de repetições CGG do gene Fragile Mental 
Retardation-1 (FMR1) e a função reprodutiva em mulheres não é uma 
novidade. Está descrito que as portadoras de alelos com um número de 
repetições CGG entre 55 e 200, designados por pré-mutação, têm uma 
predisposição para desenvolver insuficiência ovárica primária ou menopausa 
precoce. Porém, a existência de risco de diminuição da função reprodutiva nas 
mulheres, com genótipos considerados “normais” (CGG<54), e respetivos sub-
genótipos ainda não é clara. Sabe-se que a presença de interrupções AGG 
confere a esses alelos uma maior estabilidade, impedindo a expansão do 
número de repetições CGG para um tamanho considerado patogénico. A 
forma como o número e o padrão de interrupções AGG poderá influenciar a 
função reprodutiva feminina, nunca foi estudada. No presente trabalho, os 
marcadores de reserva ovárica foram correlacionados com o número de 
repetições CGG e perfil das interrupções AGG. A população em estudo incluiu 
50 mulheres jovens e saudáveis, candidatas à doação de oócitos. Dado que o 
número e o padrão das interrupções AGG não são determinados por rotina, foi 
então necessário implementar a sua análise, recorrendo a diferentes 
metodologias: 1) Triplet-Primed Polymerase Chain Reaction; 2) Sanger 
sequencing; and 3) Restriction Fragment-Length Analysis. Foi realizada uma 
projeção da associação entre o número de repetições CGG e os níveis 
hormonais, através de uma análise multivariável, considerando os novos sub-
genótipos "normais" FMR1 previamente definidos. Os níveis hormonais 
associados às diferentes amostras não foram suficientes para discriminar sub-
genótipos, indicando que a individualização das amostras classificadas por 
sub-genótipos não era possível. Recorrendo a uma fórmula matemática que 
determina a pontuação alélica, tendo em consideração o tamanho total do 
alelo, e o número e o padrão de AGG. Após análise estatística foi possível 
dividir as amostras em dois grupos: um primeiro designado por grupo 
equivalente e um segundo designado por grupo oposto. O grupo equivalente, 
que é composto principalmente por amostras que possuem alelos do sub-
genótipo “normal” FMR1, e o oposto, onde a maioria das amostras possui sub-
genótipo “normal/baixo” FMR1. No grupo equivalente, observou-se correlação 
positiva e significativa entre número de folículos antrais e os níveis hormonais: 
prolactina e hormona luteinizante (LH). Assim, é possível prever o número de 
folículos antrais produzidos combinando os níveis de prolactina e LH. Estes 
resultados confirmam publicações anteriores, já que o sub-genótipo 
“normal/baixo” foi anteriormente associado a uma diminuição da reserva 
ovárica. No geral, este estudo confirma a associação da região repetitiva CGG 
do FMR1 na função reprodutiva feminina e sugere que a estabilidade dos 
alelos é um fator determinante para o sucesso da resposta ovárica.  
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abstract 
 
The impact of the Fragile Mental Retardation-1 (FMR1) gene CGG repeat 
number in the female reproductive function is well established. Carriers of a 
CGG repeat number between 55 and 200, designated a premutation, are prone 
to develop primary ovarian insufficiency or early menopause. Yet, an impact on 
the reproductive function in carriers of “normal” genotypes and sub-genotypes 
(CGG<54) is controversial. The presence of AGG in normal-sized alleles confers 
stability, hampering the expansion of the repeat number in future generations. 
To the best of our knowledge testing the influence of the AGG number and 
pattern on the female reproductive function has never been endeavored. 
Herein, the ovarian reserve markers were correlated with CGG number as well 
as AGG number and pattern, in female carriers of FMR1 normal-sized alleles. 
Our cohort comprised 50 healthy young females, candidates for oocyte 
donation. Considering AGG number and pattern are not routinely determined 
different methodologies were implemented: 1) Triplet-Primed Polymerase 
Chain Reaction; 2) Sanger sequencing; and 3) Restriction Fragment-Length 
Analysis.  A projection of the association between the CGG repeat values and 
the hormonal levels, by multivariate analysis, was performed, considering the 
FMR1 new “normal” sub-genotypes previously defined. The hormonal levels 
associated with the different samples were not sufficient to discriminate the 
sub-genotypes, indicating that the individualization of the samples classified by 
sub-genotype was not possible. Resorting to a mathematical formula that 
determines the allelic score, taking into account total allele size, and AGG 
number and pattern. After statistical analysis, it was possible to divide the 
samples into two groups: a first called an equivalent group and a second called 
an opposite group. The equivalent group is composed mainly of samples 
carrying alleles in the normal FMR1 sub-genotype and the opposite, where 
most of the samples have an FMR1 low/normal sub-genotype. In the equivalent 
group, a positive and significant correlation was observed between the number 
of antral follicles and the hormonal levels: prolactin and luteinizing hormone 
(LH). Thus, it is possible to predict the largest number of antral follicles 
produced combining the levels of prolactin and LH. These results actually 
confirm prior publications as the low/normal sub-genotype has been previously 
associated with a diminished ovarian reserve. Overall, this study confirms the 
association of the FMR1 CGG repetitive region in the female reproductive 
function and suggests that the stability of the alleles is a determining factor for 
the ovarian response success. 
 
 
 
“The influence of the Fragile Mental Retardation-1 (FMR1) gene CGG repetitive region in the female 
reproductive function” 
 
I 
 
INDEX 
 
List of Figures ...................................................................................................................... III 
List of Tables ....................................................................................................................... IV 
List of Abbreviations and Sigla ............................................................................................ V 
Chapter 1. Introduction ............................................................................................... 3 
1. Background .................................................................................................................... 3 
2. Fragile Mental Retardation-1 gene - FMR1 ................................................................... 4 
2.1. Fragile X Syndrome - Historical overview ................................................................. 4 
2.2. FMR1 gene and coded protein .................................................................................... 4 
2.3. FMR1 allele categories ............................................................................................... 5 
2.4. Mechanisms of CGG expansion ................................................................................. 5 
2.5. Diseases caused by mutations in FMR1 gene ............................................................. 7 
2.5.1. Fragile X Syndrome (FXS) .................................................................................. 7 
2.5.2. Fragile X - associated Tremor Ataxia Syndrome (FXTAS) ................................ 7 
2.5.3. Fragile X - associated Primary Ovarian Insufficiency (FXPOI) .......................... 8 
2.6. FMR1 in female fertility ............................................................................................. 9 
2.6.1. Female FMR1 new “normal” genotypes .............................................................. 9 
2.6.2. Ovarian reserve decline ...................................................................................... 10 
2.6.3. Ovarian reserve testing and markers .................................................................. 11 
2.6.3.1. Hormonal (biochemical) markers ................................................................ 13 
2.6.3.2. Ultrasonographic marker ............................................................................. 14 
3. Objectives of the thesis ................................................................................................ 15 
4. Thesis organization ...................................................................................................... 16 
References ........................................................................................................................... 17 
“The influence of the Fragile Mental Retardation-1 (FMR1) gene CGG repetitive region in the female 
reproductive function” 
 
II 
 
Chapter 2. The impact of the FMR1 gene AGG interspersions in the female 
reproductive function .................................................................................................. 25 
Abstract ................................................................................................................................ 25 
1. INTRODUCTION ........................................................................................................ 27 
2. MATERIAL AND METHODS ................................................................................... 28 
2.1. Pilot study ................................................................................................................. 28 
2.2. Triplet-primed polymerase chain reaction (TP-PCR) ............................................... 29 
2.3. Sanger Sequencing .................................................................................................... 30 
2.4. Restriction-fragment length analysis (RFLA) .......................................................... 31 
2.5. Statistical analyses .................................................................................................... 31 
3. RESULTS & DISCUSSION ........................................................................................ 33 
References ........................................................................................................................... 40 
Chapter 3. Discussion and future perspectives .......................................... 45 
ANNEXES .......................................................................................................................... 44 
 
 
“The influence of the Fragile Mental Retardation-1 (FMR1) gene CGG repetitive region in the female 
reproductive function” 
 
III 
 
List of Figures  
 
Figure I. Schematic representation of FMR1 gene regions ………………….……………...5 
Figure II. Categories of FMR1 alleles………………………….………......……………….6 
Figure III. Schematic representation of the effect caused by the different categories of 
FMR1 alleles……………………………………………………...………………………....9 
Figure IV. Graphical representation of the follicle number according to age ……………..11 
Figure V. Schematic representation of folliculogenesis ……………………….……….....12 
Figure 1. Biplot of FMR1 sub-genotypes biochemical results (for the 50 potential oocyte 
donors).……………………...………………………………………………..……………35 
Figure 2. Allelic complexity score value of each sample…………………………………..36 
Figure 3. Allelic complexity score value based on the allele size and AGG interruptions 
number and pattern.………………………………………………………………………..36 
Figure 4. Isobologram showing the visual representation of the mathematical 
formula………………………………………………………………………………….…38 
 
 
 
 
 
 
 
 
 
“The influence of the Fragile Mental Retardation-1 (FMR1) gene CGG repetitive region in the female 
reproductive function” 
 
IV 
 
List of Tables  
 
Table I. Normal FMR1 sub-genotypes..…..………………………………………………10 
Table II. Reference values ovarian reserve markers…………………………...…….……14 
Table 1. Sequence of primers used in TP-PCR…………………………………………….29 
Table 2. Triplet-primed PCR components……………………………………………........29 
Table 3. Sequence of primers used in sequencing PCR reactions…………...……………..30 
Table 4. Symmetric PCR components……………………………………………………..30 
Table 5. Asymmetric PCR components……………………………………………………31 
Table 6. Summary of FMR1 genotyping data in the cohort of 50 potential oocyte donor 
samples…………………………………………………………………………………….33 
Table 7. Summary of donor characteristics and biochemical data………………………....34 
Table 8. Samples distributed according to allelic complexity score groups and FMR1 CGG 
sub-genotypes…………………………………………………………............………...…37 
  
“The influence of the Fragile Mental Retardation-1 (FMR1) gene CGG repetitive region in the female 
reproductive function” 
 
V 
 
List of Abbreviations and Sigla  
 
AMH - Anti-Müllerian Hormone  
CHP - Centro Hospitalar do Porto  
CMIN – Centro Materno Infantil do Norte  
DMSO - Dimethyl Sulfoxide 
DNA - Deoxyribonucleic Acid 
DOR - Diminished Ovarian Reserve  
E2 - Estradiol  
FM - FMR1 Full Mutation  
FMR1 - Fragile Mental Retardation 1 gene  
FMRP - Fragile Mental Retardation Protein  
FOR - Function of Ovarian Reserve  
FSH - Follicle-Stimulating Hormone  
FXPOI - Fragile X - associated Primary Ovarian Insufficiency 
FXS - Fragile X Syndrome  
FXTAS - Fragile X - associated Tremor/Ataxia Syndrome  
GnRH - Gonadotropin-Releasing Hormone 
ID - Intellectual Disability  
IVF - In vitro Fertilization  
Kb - Kilobases 
LH - Luteinizing Hormone  
MAP - Medically Assisted Procreation 
“The influence of the Fragile Mental Retardation-1 (FMR1) gene CGG repetitive region in the female 
reproductive function” 
 
VI 
 
PCR - Polymerase Chain Reaction  
PM - FMR1 Premutation  
POF - Premature Ovarian Failure   
PRL - Prolactin  
RNA - RiboNucleic Acid 
tAFC - Total Antral Follicle Count in both ovaries.  
TP-PCR - Triplet-Primed Polymerase Chain Reaction  
UTR - Untranslated Region 
 
 
  
 
 
 
 
 
 
“The influence of the Fragile Mental Retardation-1 (FMR1) gene CGG repetitive region in the female 
reproductive function” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1. 
___________________________________________ 
                                                                              Introduction  
 
 
 
 
“The influence of the Fragile Mental Retardation-1 (FMR1) gene CGG repetitive region in the female 
reproductive function” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“The influence of the Fragile Mental Retardation-1 (FMR1) gene CGG repetitive region in the female 
reproductive function” 
 
3 
 
Chapter 1. Introduction  
1. Background 
Infertility is clinically defined as a disease of the reproductive system characterized by 
the inability to achieve a pregnancy after a year or more of unprotected sexual activity 
(ESHRE, 2013). According to the most recent estimates about 9% of couples have infertility  
problems (Boivin et al., 2007). Infertile female due to ovarian failure can pursue fertility 
treatments and conceive following in vitro fertilization (IVF) techniques resorting to oocyte 
donation (ESHRE, 2013). Oocyte donation is the process by which a fertile and healthy 
female allows several of her oocytes to be aspirated, usually following ovarian stimulation.  
The Portuguese Public Bank of Gametes is a service provided by the Portuguese 
National Health Service responsible for the recruitment and selection of oocytes and sperm 
donors. Gametes resulting from volunteer donations are then used in Medically Assisted 
Procreation (MAP) techniques. The collection and preservation of the gametes is carried out 
in public specialized Centers, namely at the Banco de Gametas – Centro de Procriação 
Medicamente Assistida, Centro Materno Infantil do Norte, (CMIN), Centro Hospitalar do 
Porto (CHP, E.P.E.). In females, the process involves a set of three steps ranging from 
candidate selection, to hormonal stimulation and donation (oocytes harvest). In the selection 
phase, several studies are carried out including psychological, blood tests and reproductive 
function evaluation i.e. ovarian reserve tests. These are of importance in potential oocyte 
donors to evaluate the ovarian reserve and subsequently determine the gonadotrophin dosage 
prior to the stimulation. Blood tests include exclusion of sexually transmitted diseases and 
genetic analyses. The latter comprise karyotype and molecular screening for cystic fibrosis 
causing mutations and FMR1 premutation or full mutation alleles. Testing for both genetic 
disorders is justifiable by the high incidence of carriers in the general population (Hantash 
et al., 2011). In an oocyte donor, the presence of an FMR1 premutation besides the risk of 
expanding to a full mutation causing fragile X syndrome in the fetus, predisposes to a 
premature ovarian failure (POF) causing a fertility issue in the potential donor (Schenkel et 
al., 2016). The association between FMR1 CGG number and infertility is not new. Recent 
studies however have shown some evidence that this gene can also be associated with other 
forms of ovarian dysfunction beyond FXPOI (Gleicher et al., 2015). 
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The work described in this thesis aims to shed light on the influence of the FMR1 gene 
CGG repeat length and stability in the female reproductive function. To the best of our 
knowledge this was never attempted before. The cohort of potential oocyte donors, which 
usually includes healthy females aging from 18 to 33 years, characterized on both hormonal 
and genetic profiles, was considered a good control population for these studies. Herein, data 
from fifty potential donors recruited at the Banco de Gametas, CMIN, CHP, E.P.E. - between 
2014 and 2016, were used. 
 
2. Fragile Mental Retardation-1 gene - FMR1  
 
2.1. Fragile X Syndrome - Historical overview  
 Fragile X syndrome (FXS; OMIM #3000624) is the most common cause of inherited 
intellectual disability (ID) and the second most frequent cause of ID of genetic origin 
(Saldarriaga et al., 2014). Anciently the diagnosis of FXS was made by cytogenetic 
techniques through the identification of an unusual constriction at the distal end of the long 
arm of the X chromosome (fragile site), which was called the "marker X chromosome" 
(Lubs, 1969). In 1991, the Fragile  Mental Retardation-1 gene (FMR1; OMIM #309550) was 
identified and established as the underlying cause of FXS (Verkerk et al., 1991).  
 
2.2. FMR1 gene and coded protein  
 FMR1 gene is located on the long arm of the X chromosome at Xq27.3 and is composed 
by 17 exons spanning approximately 40 Kilobases (Kb).  Near the gene promoter at 5’UTR 
a CpG island and a triplet repetitive and polymorphic region composed by CGG is present 
(Jin and Warren, 2000; Wittenberger et al., 2007) (Figure I).  
 FMR1 gene codes for the fragile X mental retardation protein (FMRP), a selective RNA-
binding protein that shuttles between the nucleus and the cytoplasm (Kline et al., 2014). 
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FMRP is present in neurons, primordial germ cells and granulosa cells of developing ovarian 
follicles (Sullivan et al., 2011).  
 
 
In neurons, FMRP can also be found at the base of dendritic spines and is suggested to 
participate in the process following synaptic activity. These findings indicate that the 
absence of FMRP may directly influence neuronal plasticity and thus cause ID in FXS 
patients (Wittenberger et al., 2007; Hoyos and Thakur, 2017).  
 
2.3. FMR1 allele categories   
Depending on the number of the CGG repeats, four types of alleles can be defined 
(Biancalana et al., 2015). In the normal population both normal alleles, that have up to 44 
CGG repeats, and intermediate or gray zone alleles, with 45 to 54 CGGs, can be observed. 
The latter can show some degree of instability particularly in meiosis. Alleles with 55 to 200 
CGGs are defined as premutations (PM), while alleles containing more than 200 CGG 
repeats as full mutations (FM), these are usually completely methylated (Schenkel et al., 
2016). Both of these pathogenic mutations can be unstable upon transmission causing 
different phenotypes described in detail below (Biancalana et al., 2015) (Figure II).  
 
2.4. Mechanisms of CGG expansion  
Normal-sized alleles are considered stable, e. g., there is usually no change in CGG 
number when transmitted to the next generation, unlike premutation or full mutation alleles 
that are considered unstable. The instability in the transmission of intermediate alleles is still 
debatable. Although the molecular causes of the CGG expansion are not fully understood, 
there are some risk factors (Maia et al., 2016).  
Figure I. Schematic representation of the FMR1 gene regions (not at scale). 
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Commonly, the polymorphic region the FMR1 gene 5’UTR is not composed by pure 
CGG triplets. The number of CGG repeats in the general population is highly variable (the 
most frequent allele has 29 or 30 repeats and carrying an AGG interruptions after the ninth 
or tenth CGG (Oostra and Willemsen, 2003; Maia et al., 2016). These AGG interspersions 
are proposed to be the anchor that avoid DNA slippage during DNA replication. Thus, it is 
believed that the repeats are more stable when interrupted with AGGs.  On the contrary, the 
loss of an interruption resulting in a long pure CGG sequence at the 3′ end contributes to 
instability and replication errors. The longer the 3′ pure CGG, the more susceptible is to 
further expansion. The instability of this region seems to be associated not only with the 
number, but also with the pattern of the interruptions (Eichler et al., 1994; Poon et al., 2006). 
In the majority of premutation and full mutation alleles, no AGG interruption is observed 
(Penagarikano et al., 2007). 
 
 
Figure II. Categories of FMR1 alleles.            
Allele classes divided according to CGG repeat number and respective clinical effect: FXTAS -
Fragile X Tremor/Ataxia Syndrome; FXPOI - Fragile X Primary Ovarian Insufficiency; FXS -
Fragile X Syndrome. Image provided by Laboratório de Genética Molecular, CGMJM, CHP, E.P.E.
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2.5. Diseases caused by mutations in FMR1 gene 
 
2.5.1. Fragile X Syndrome (FXS) 
Fragile X syndrome is a neurodevelopmental condition with an estimated incidence of 
1 in 4000 males and 1 in 4000-8000 females (Jin and Warren, 2000). The typical 
characteristics of this syndrome include moderate to severe ID, macroorchidism and distinct 
facial features: long face and protruding ears (Saldarriaga et al., 2014; Schenkel et al., 2016). 
The majority of FXS patients has an expansion of more than 200 CGGs. These CGG 
expansions result in the hyper-methylation of FMR1 promotor which hampers transcription 
and consequently leads to gene silencing. The clinical features associated to the FXS are 
caused by absence of the protein coded by this gene, FMRP (Schenkel et al., 2016; Hoyos 
and Thakur, 2017). Other rare mutational mechanism, such as FMR1 deletions or even rarely 
missense mutations can cause FXS (Schenkel et al., 2016).   
 
2.5.2. Fragile X - associated Tremor Ataxia Syndrome (FXTAS) 
FXTAS (FXTAS; OMIM #300623) is a late-onset (> 50 years) progressive 
neurodegenerative disorder that affects premutation carriers of both sexes (Wittenberger et 
al., 2007; Wang et al., 2017). This syndrome has a penetrance of around 40% in males and 
between 8% and 16% in females (Hoyos and Thakur, 2017). In males, the risk of developing 
FXTAS increases with age (Wittenberger et al., 2007). The lower penetrance of FXTAS 
among females can be explained by the “protective” effect of the normal and active X 
chromosome due to the random X- chromosome inactivation (Wittenberger et al., 2007).  
The premutation alleles are not methylated, therefore the synthesis of  FMRP occurs at a 
level below the normal (Schenkel et al., 2016).  
Clinical features of FXTAS include progressive intention tremor, gait ataxia (resulting 
on frequent falls), cognitive deficits (executive function and memory problems), 
psychological features (anxiety, depression, mood lability, outburst or reclusive behavior), 
autonomic dysfunction, parkinsonian features and peripheral neuropathy with diminished 
sensation in the lower extremities. FXTAS brain magnetic resonance image shows 
progressive global brain atrophy and white matter disease of both cerebellum and cerebrum.  
“The influence of the Fragile Mental Retardation-1 (FMR1) gene CGG repetitive region in the female 
reproductive function” 
 
8 
 
Before the onset of tremor or ataxia it is possible to detect cerebellar and brainstem atrophy 
and ventricular enlargement (Wittenberger et al., 2007; Wang et al., 2017) . 
 
2.5.3. Fragile X - associated Primary Ovarian Insufficiency (FXPOI)  
Fragile X primary ovarian insufficiency (FXPOI; OMIM #311360) is a disorder defined 
as cessation of menses (menopause) before age 40 years, also known as premature ovarian 
failure (POF) (Voorhuis et al., 2013). 
The diagnosis is based on amenorrhea for at least 4 months and elevated serum follicle-
stimulating hormone (FSH) levels in the menopausal range (usually above 40IU/mL). This 
syndrome presents other characteristics, such as shorted follicular phases and low anti-
Müllerian (AMH) levels (Streuli et al., 2009; Tural et al., 2014;  Eslami et al., 2016). 
Premature ovarian failure is clearly an heterogeneous disorder with at least 13 distinct loci 
identified so far (/www.omim.org/entry/311360; assessed on 2017/08/5). POF1 locus 
located within Xq26-q28 region is associated with the premutation in the FMR1 gene 
(Eslami et al., 2016).  
 Female full mutation carriers do not develop ovarian dysfunction, which suggests that 
the mechanism underlying this clinical entity is not caused by the absence of the FMRP 
(Streuli et al., 2009).  In the premutation range, FMRP is expressed but the FMR1 mRNA 
levels are increased causing FMR1 mRNA protein complexes, which accumulate and 
interfere in the normal cell function, and eventually cell death (Ruth et al., 2016). The 
increase of FMR1 mRNA transcription level is proportionally related to the number of CGG 
in the premutation range (Streuli et al., 2009 ). However, the risk of FXPOI  is greater in 
carriers of premutated alleles from 80 to 100 CGGs than in those with higher repeat number 
(Voorhuis et al., 2013) (Figure III). 
Ovarian dysfunction is believed to be caused by a toxic effect due to the accumulation 
of FMR1 mRNA in ovarian cells (granulose and oocyte cells), leading to follicular atresia 
and impairing follicle development, by a mechanism that remains to be elucidated (Sullivan 
et al., 2005; Willemsen et al., 2011).   
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2.6. FMR1 in female fertility  
The association of FMR1 gene with female infertility is not surprising as it is long 
known that carriers of  a premutation ( 55≤[CGG]≤200) have increase risk for POF (Gleicher 
et al., 2015). The association of the FMR1 gene with other forms of ovarian dysfunction 
such as pathologic diminished ovarian reserve (DOR), have also been described but are less 
clear (Pfeifer et al., 2015).  
 
2.6.1. Female FMR1 new “normal” genotypes  
Based on their work on FMR1 and ovarian function, recently Gleicher et al., (2014) 
suggested a new normal range sub-genotype: 26≤[CGG]≤34. These authors have shown that 
carriers of both or one allele with a repeat number above or below this “new” normal range 
are in risk of  DOR (Gleicher et al., 2014). Several new normal FMR1 sub-genotypes are 
being considered (Table 1).  
Figure III. Schematic representation of the effect caused by the different categories of FMR1 
alleles (adapted from Wittenberger et al., 2007).   
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This subject is controversial and is still under discussion, since several studies seem to 
have contradictory conclusions. Some authors found  no relation between normal/high or 
intermediate-sized alleles and premature ovarian failure or DOR (Bennett et al., 2010; 
Murray et al., 2014 ; Kline et al., 2014 ; Voorhuis et al., 2014). A different study with 1,287 
infertile woman suggests no correlation between alleles with a CGG number between 35 and 
54 and the ovarian reserve markers FSH, AMH or antral follicles count (Schufreider et al., 
2015).  
Thus, it is still unclear whether FMR1 alleles in the normal range are associated with 
diminished ovarian reserve and if the repeat length confers risk for diminished fertility. 
 
Sub-genotype 8<[CGG]<26 26<[CGG]<34 34<[CGG]<55 
normal  A1 and A2  
normal/high  A1 A2 
low/normal A1 A2  
low/high A1  A2 
high/high   A1 and A2 
low/low A1 and A2   
 
2.6.2. Ovarian reserve decline  
The ovary contains a finite number of oocytes, called the ovarian reserve, that are subject 
to maturation to reach the ovulatory stage. Ovarian reserve is characterized by the 
reproductive potential as a function of the number and quality of remaining oocytes (Pfeifer 
et al., 2015 ; Eslami et al., 2016). A fecundity decay is associated with ovarian follicular 
depletion and decreased oocyte quality (Verissimo and Silvestre, 2016). A reduction in the 
quantity and quality of aged oocytes is a normal physiological occurrence, however some 
females show a premature decline of the ovarian reserve (Pastore et al., 2014) (Figure IV). 
A diagnosis of DOR is  attributed to females at reproductive age, having regular menses, 
Table I. Normal FMR1 sub-genotypes.  
A1- Allele with smallest CGG repeat number; A2- Allele with largest CGG repeat number. 
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with reduced ovarian stimulation or fecundity, when compared with normal females of 
similar age (American Society for Reprodutive Medicine, 2015). Females with DOR may 
have reduced fecundity, or a limited response to ovarian stimulation with fertility 
medications. However, DOR does not directly imply an inability to conceive (Man et al., 
2017).  
Various circumstances can have an adverse effect on the ovarian function, but in most 
cases the exact cause of DOR is unknown (Pfeifer et al., 2015). Some examples of those 
conditions are: aging, environmental factors (e.g. smoking), autoimmune diseases, 
iatrogenic agents (e.g. chemotherapy), endometriosis with ovarian involvement and genetic 
abnormalities (Pfeifer et al., 2015 ; Eslami et al., 2016).   
 
2.6.3. Ovarian reserve testing and markers  
The possibility of knowing the ovarian reserve at a given point assumes a clinical 
importance, not only to evaluate the follicular pool but also to predict the physiological 
ovarian failure and terminus of the conception capacity (Verissimo and Silvestre, 2016).  
Figure IV.  Graphical representation of the follicle number according to age 
(http://www.eggfreezing.org.uk/assessed on 2017/09/21).  
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Ovarian reserve markers can be divided into: 1) biochemical markers and 2) ultrasound 
markers. Biochemical markers usually include measuring the serum levels of AMH, 
estradiol, FSH, inhibin B, LH and Prolactin. The determination of total antral follicle count 
in both ovaries corresponds to the ultrasonographic marker  (Pfeifer et al., 2015). Figure V 
shows the process of follicle maturation from the primordial follicle to the ovulatory follicle 
(folliculogenesis) and the role of different hormones in this process.  
 
 
Figure V. Schematic representation of folliculogenesis (from Visser et al., 2012) 
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2.6.3.1. Hormonal (biochemical) markers  
 
 Anti-Müllerian hormone (AMH)  is a glycoprotein produced by granulosa cells of pre-
antral follicles and small antral follicles as soon as the primordial follicles are recruited 
(Pfeifer et al., 2015 ; Verissimo and Silvestre, 2016). AMH is a gonadotropin-independent 
hormone and therefore remains relatively consistent within and between menstrual cycles. 
Low AMH levels have been associated to a poor response to ovarian stimulation, embryo 
quality and pregnancy outcomes in IVF (Pfeifer et al., 2015).  
Estradiol (E2)  is a steroid hormone produced by ovarian follicles of the granulosa cells 
(Verissimo and Silvestre, 2016). Basal estradiol has a poor inter- and intra-cycle reliability, 
thereby it  should not be used alone as a measure for function ovarian reserve (Pfeifer et al., 
2015). In the early follicular phase, when the estradiol level is elevated and the basal FSH 
concentration is normal, there is no evidence of an association between poor ovarian 
response and low pregnancy rates in IVF treatments (Pfeifer et al., 2015 ; Verissimo and 
Silvestre, 2016).  
Follicle-stimulating hormone (FSH) is secreted by the anterior pituitary gland and 
plays an important role in the recruitment and maturation of primordial follicles and the 
induction of ovarian estrogen productions via the aromatase enzyme. A diminished follicular 
pool leads to a decrease in the estradiol and inhibin B production and, consequently, an 
increase of FSH (Verissimo and Silvestre, 2016). High FSH values have been associated to 
a diminished ovarian reserve. However, FSH test, shows significant inter-and-intra cycle 
variability, which is a limitation (Pfeifer et al., 2015).  
Inhibin B is secreted by the ovary granulosa and teak cells.  It inhibits the FSH secretion 
and has a paracrine action in the follicles development. An inhibin B decrease on the third 
day of the menstrual cycle may predict a low ovarian reserve. However, inhibin B is not a 
reliable measure because its levels can increase after gonadotropin-releasing hormone 
(GnRH) or FSH stimulation, exhibiting high intra-cycle variability (Pfeifer et al., 2015). 
 Luteinizing hormone (LH) is a hormone secreted by the adenohypophysis to stimulate 
the formation of the yellow body in the ovaries at the Graaff follicle rupture site, in order to 
produce progesterone. LH plays an essential role in oocyte maturing and development, in 
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IVF cycles (Canêdo, 2015). An elevated (>3,6 mUI/mL) FSH:LH ratio, determined on day 
3 of the cycle,  can be a signal of DOR (Mukherjee et al., 1996 ;  Roudebush et al., 2008).  
 Prolactin (PRL) is the secreted by the adeno-hypophysis and its main function is to 
stimulate the production of milk by the mammary glands Hyperprolactinemia, can cause 
menses alteration and infertility (Melmed et al., 2011).  
 
2.6.3.2. Ultrasonographic marker  
 
Antral Follicle Count (AFC) – The total antral follicle count corresponds to the total 
number of antral follicles, measuring between 2-10 mm in diameter, in both ovaries, seen 
with transvaginal ultrasound during the early follicle phase. A low AFC number (3-6 total 
antral follicles) is considered a predictor of poor ovarian response and pregnancy outcomes 
after IVF. A significant correlation was observed between the antral follicles and the number 
of oocytes obtained after FSH stimulation. The clinical utility of AFC is limited due to its 
intra- and inter- cycle variability (Pfeifer et al., 2015 ; Verissimo and Silvestre, 2016).   
Table II shows serum hormonal reference values and antral follicles number. Potential 
oocyte donors are exclued if one of these values falls outside reference value establishsed by 
Banco de Gametas, CMIN, CHP, E.P.E.  
 
Markers Refence values* 
FSH <10 mIU/mL 
Inhibin B <40 pg/mL 
Estradiol <60 pg/mL 
FSH:LH <3,6 mUI/mL 
Prolactin <25 ng/mL 
AFC >6 tAFC 
Table II. Reference values ovarian reserve markers.  
*Established by Banco de Gametas, CMIN, CHP, E.P.E.  
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Overall, there is no consensus on the test, or combination of measures to best  evaluate 
the ovarian reserve. Several authors suggest that AFC  combined with serum AMH show a 
good descriminatory potential as ovarian reserve predictors. The AMH has no inter cyclic 
variability and AFC has the advantage of being noninvasive (compared with hormonal tests) 
and its variation between cycles do not affect the ovarian response (Verissimo and Silvestre, 
2016).  
 
3. Objectives of the thesis  
The present thesis endeavors to evaluate the influence of the FMR1 gene on the ovarian 
reserve. The association between FMR1 CGG number and the reproductive function in 
healthy females will be investigated. Considering the CGG repeat is interrupted by AGG, in 
the majority of normal-sized/control alleles, not only the size of the repeat but also the pattern 
of the AGG interruptions will be considered. No previous literature reports were found 
describing a similar approach in normal sized-alleles.  
Anonymized data from 50 potential oocyte donors were obtained from Banco de 
Gametas of the Centro de Procriação Medicamente Assistida – CMIN, CHP, E.P.E. The data 
includes: age at first consultation, total antral follicle count and serum levels of Estradiol, 
FSH, LH, and Prolactin. FMR1 CGG repeat number (100 alleles) was determined at Centro 
de Genética Médica Doutor Jacinto Magalhães – CHP, E.P.E. 
Specific aims of the present work include: 
a) Statistical analysis aiming a correlation between hormonal levels and FMR1 CGG repeat 
number.    
b) Determination of the AGG pattern of the 100 alleles using different methodologies: 
Triplet-primed PCR, Sanger sequencing and restriction fragment analysis.  
c)  Establish the influence of FMR1 CGG number and AGG pattern on the ovarian reserve 
and ultimately in the female fertility.  
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4. Thesis organization 
The present thesis is organized in three chapters. The first chapter provides a broad 
introduction addressing literature review on FMR1 gene, associated phenotypes and its role 
in female fertility. Chapter 2 is structured as a scientific paper submitted to Fertility and 
Sterility Journal. A broader discussion of results provided in the paper as well as future 
perspectives of this thesis work are detailed in Chapter 3. Annexes 1-3 contain 
supplementary data of chapter 2 results. Annex 4 include other scientific work focusing on 
subjects not directly linked to the main goal of this thesis. 
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Chapter 2. The impact of the FMR1 gene AGG interspersions in 
the female reproductive function 
 
Abstract  
Objectives – Albeit still controversial an association between FMR1 gene CGG allele size 
below 26 and a low ovarian reserve has been reported.  Furthermore, to the best of our 
knowledge, the effect of the AGG interspersions of those normal-sized alleles and their 
impact on the ovarian function was never tested. The aim of this study was to assess the 
influence of the FMR1 gene in the female reproductive function and ovarian reserve by 
establishing a measure of the allele complexity, combining GGC number and AGG pattern.   
Design - Young and healthy females.  
Setting – Centro de Genética Médica Doutor Jacinto Magalhães – Centro Hospitalar do 
Porto.  
Patients – Fifty potential oocyte donors aged between 18 and 33 years and corresponding 
results of hormonal, genetic, and reproductive studies previously obtained as part of routine 
donor selection protocol. FMR1 allele sizes were organized by hitherto defined classes of 
sub-genotypes. 
Results - The multivariate analysis showed that the hormonal levels are not sufficient to 
discriminate samples according to the FMR1 sub-genotypes. We hypothesized that besides 
the length of the CGG tract also the AGG interspersion pattern could be implicated in the 
female reproductive function. A mathematical formula was further established to score the 
allelic complexity. At an allelic score value of 122, two distinct groups emerged: the 
equivalent, composed mainly by samples carrying alleles in the normal sub-genotype and 
the opposite, where most of the samples have a low/normal allele. 
Conclusion – Overall, this study confirms the importance of FMR1 gene CGG tract in the 
female reproductive function and highlights that the stability of those alleles, determined by 
the AGG number and pattern, is also an important factor. To assess FMR1 influence in the 
female ovarian function we suggest the additional determination of the AGG number and 
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pattern as a measure of allelic complexity. To establish whether the AGG pattern can 
determine the ovarian response in IVF treatments or oocyte donor selection and be 
meaningful to changes in the clinical practice, studies in larger and at-risk cohorts (e.g. 
infertile couples) are needed. 
 
Keywords – CGG repeat number; reproductive function; AGG interspersions; ovarian 
reserve markers; oocyte donors  
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1. INTRODUCTION  
Fragile X-associated primary ovarian insufficiency (FXPOI; OMIM#311360) is 
characterized by an ovarian reduced function and accounts for about 5% of all cases of 
primary ovarian insufficiency (1). FXPOI can cause early menopause, irregular cycles, 
elevated follicle stimulating hormone (FSH) levels and ultimately lead to infertility (2–4). 
Fragile mental retardation-1 gene (FMR1) mutations in the premutation range (CGG number 
between 55 and 200) augment the risk of FXPOI, in about 15 to 20%, when compared to an 
healthy population (3,5). Shortened follicular phases and changes in several ovarian function 
biochemical markers, such as raised FSH and low anti-Mullerian hormone (AMH) levels, 
have also been described in FMR1 premutation carriers (2). Bellow 54 CGG repeats, alleles 
are classified as normal and usually carry two or more AGG interruptions which is assumed 
to give stability, hampering the expansion to pathogenic ranges (6,7).  Among the normal 
range, alleles with 45 to 54 CGGs are known as intermediate or gray zone, due to the 
likelihood of expansion (in two or three generations) (8,9). When this expansion is in full 
mutation range the simultaneous hypermethylation of the repetitive region and the FMR1 
promoter, as well as gene silencing, occur. FMR1 transcriptional inactivation and the 
consequent absence of the coded protein, FMRP, is the cause of the intellectual disability in 
patients with fragile X syndrome [FXS; OMIM#300624] (9,10). FXS includes also learning 
problems, autistic behaviour and typical physical features, such as long and narrow face and 
protruding ears (9,11). FMRP plays a role in the development of connections at synapses 
(10,12). Although arising from mutations in the same gene, different mechanisms lead to 
FXS and FXPOI (2). The FMRP implication in the ovarian function, remains to be 
unravelled, although it is established that the premutation triggers the overproduction of 
FMR1 mRNA that leads to a process of RNA toxicity (5,13,14).  
Recent reports of phenotypes that overlap to those seen in females with a premutation 
or are exclusive to normal/intermediate size carriers has grown interest in this latter range of 
alleles. Conclusions however, are controversial, not only regarding influence of FMR1 in 
ovarian reserve but also on definition of a “new” normal repeat range applicable exclusively 
to the female reproductive function. Gleicher, and co-workers (2015), published several 
studies showing the influence of the CGG repeat number in the ovarian reserve. In another 
study, an AMH decline, suggestive of diminished ovarian reserve, was observed to occur 
more rapidly in oocyte donor candidates carrying one allele with a CGG number below 26 
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(15). In a cohort of infertile women, lower AMH levels were associated with presence of 
one allele with less than 28 and the other with more than 33 repeats (16). Spitzer et al., on 
the contrary, has found no such associations when studied a similar but larger cohort (17) . 
To better understand the impact of the FMR1 normal range genotypes and sub-
genotypes we investigated if the AGG interspersions also play a role in the female ovarian 
function. Since hormonal levels and antral follicle counts seem to be associated with those 
“new-normal” FMR1 genotypes we studied the effect of AGG number and pattern in a pilot 
study of 50 potential oocyte donors. Overall, this study confirms the association of the FMR1 
CGG repetitive region in the female ovarian function and suggests that the stability of the 
alleles – determined by AGG number and pattern – is also a determining factor for the 
ovarian response success. 
 
 
2. MATERIAL AND METHODS 
2.1. Pilot study  
The Public Bank of Gametes is a service provided by the National Health Service 
responsible for the recruitment and selection of oocytes and sperm donors. Gametes resulting 
from volunteer donations are then used in Medically Assisted Procreation techniques. The 
collection and preservation of the gametes is carried out in public specialized Centers, 
namely Centro Materno Infantil do Norte (CMIN) of Centro Hospitalar do Porto (CHP, 
E.P.E.).  Herein, results from 50 potential oocyte donors, aged between 18 and 33 years 
(mean 25,4 ± 3,9), obtained as routine protocol for donor selection were used, namely 
hormonal (Estradiol, FSH, LH and Prolactin levels), reproductive (number of antral follicles, 
tAFC) and genetic (FMR1 gene allele sizing) (annex-1). 
Further molecular studies were performed on stored genomic DNA previously extracted 
from peripheral blood using ArchivePure DNA Cell/Blood Kit (5 Prime® GmbH, Hamburg, 
Germany).  
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2.2. Triplet-primed polymerase chain reaction (TP-PCR) 
 AGG interspersion pattern was determined by TP-PCR, using primers and components 
described on Table 1 and 2, respectively.  The amplification program included 10 min 
incubation at 98°C, and 48 cycles of denaturation at 98°C for 1 min, annealing at 60°C for 
1 min and extension at 68°C for 6 min, the final extension of 10 min was performed at 68°C. 
Products were resolved on ABI PRISM® 3130xl Genetic Analyzer (Applied BiosystemsTM, 
Foster City, CA, USA), AGG pattern was analyzed using GeneMapper® software version 
4.0 (Applied BiosystemsTM) and allele sizing were obtained by comparison with the 500 
ROXTM size standard (Gene ScanTM, Warrington, UK) (annex-2). 
 
 
 
Primer Sequence 
g.FMR1_CGG_F 5’-GACGGAGGCGCCGCTGCCAGG-3’ 
g.FMR1_CGG_R* 
(6-FAM labeled) 5’-TACGCATCCCAGTTTGAGACG-3’ 
g.FMR1_P4_CGG 5’-TACGCATCCCAGTTTGAGACGCGGCGGCGGCGGCG-3’ 
Reagents  
Multiplex PCR Master Mix (Promega®, Madison, WI, USA) 1X 
Betaine (Sigma-Aldrich®, St. Louis, Missouri, EUA) 1,1 M 
DMSO (Sigma-Aldrich®) 11% 
g.FMR1_TP-PCR_F 5 pmol 
g.FMR1_ TP-PCR _R [6-FAM labeled] 5 pmol 
g.FMR1_P4_CGG 2,5 pmol 
DNA 150 ng 
Table 1. Sequence of primers used in TP-PCR. 
Table 2. Triplet-primed PCR components.   
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2.3. Sanger Sequencing 
To validate TP-PCR results, samples were sequenced using standard conditions (Tables 
3 and 4). Symmetric PCR products were purified using the enzymatic PCR clean up 
technology -IllustraTM ExoProStarTM 1-step (GE Healthcare Life Sciences, Little Chalfont, 
Buckinghamshire, UK) according to the manufacturer’s instructions. Asymmetric 
amplification (Table 5) consisted of  6 min incubation at 95°C and 35 cycles of denaturation 
at 96°C for 10 sec, annealing at 50°C for 10 sec and extension at 60°C for 4 min, the final 
extension of 10 min was performed at 60°C. Following gel filtration spin columns cleanup 
(DyeEx®96 kit, QIAGEN GmbH, Hilden, Germany), products were electrophoresed on an 
ABI PRISM® 3130xl Genetic Analyzer (Applied BiosystemsTM) and analyzed 
using SeqScape® software version 2.5 (Applied BiosystemsTM)  (FMR1 cDNA reference 
sequence NM_002024).  
 
 
 
 
 
Primer Sequence  
g.FMR1_CGG_F 5’-TGACGTGGTTTCAGTGTTTAC-3’   
g.FMR1_CGG_R  5’-AGCCAAGTACCTTGTAGAAAGCG-3’  
Reagents 
Distilled water  5,8 µL 
Accu Taq LA Buffer (Sigma-Aldrich®) 1X 
Betaine (Sigma-Aldrich®) 1,5 M 
dATP/dCTG/dTTP/dGTP (Bioline, London, UK) 0,16 mM 
DMSO (Sigma-Aldrich®) 6,3% 
g.FMR1_CGG_F 10 pmol 
g.FMR1_CGG_R 10 pmol 
DNA 150 ng 
Accu Taq LA DNA polymerase (Sigma-Aldrich®) 2 U 
Table 3. Sequence of primers used in sequencing PCR reactions.  
Table 4. Symmetric PCR components.  
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2.4. Restriction-fragment length analysis (RFLA) 
Samples showing a complex AGG pattern were further analyzed by RFLA after MnlI 
digestion of amplification products using the primers described on table 3. The incubation 
was performed at 37°C overnight using the total PCR volume (20µl) in 1X NEBuffer 4 (New 
England BioLabs®, Ipswich, Massachusetts, EUA) and 0,015 U of MnlI endonuclease (New 
England BioLabs®). Products were analyzed by agarose gel electrophoresis for sizing, by 
comparison with GeneRulerTM 100 bp Plus (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA). Fragment images were obtained by the Fujifilm Luminescent Image 
Analyzer LAS-3000 v2.2 (Fujifilm, Tokyo, Japan). MnlI recognizes the sequence 
3’…GGAG(N)6…5’, cutting the amplified sequence in a fragment of 141bp (in case of 
alleles with 29 pure CGGs) and fragments of 37, 33, 25, 20 and 13 bp, irrespectively of the 
CGG repeat number.  In the presence of 2 AGG interruptions  a 29 CGG allele will yield 
fragments with 58, 53 and 30bp. The expected size of each allele was calculated using the 
NEBcutter® version 2.0 simulator (New England BioLabs®).  
 
2.5. Statistical analyses  
Analyses were carried out using FMR1 genotypes and hormonal levels data of all 50 
potential oocyte donors (100 alleles) irrespective of the possible inclusion as donors.  
Several sets of analyses were carried out: 
Reagents  
Purified symmetric PCR product  7 µL 
BigDye® Terminador version 3.1 Cycle 
Sequencing Mix (Applied BiosystemsTM) 3 µL 
DMSO (Sigma-Aldrich®) 3,4% 
Betaine (Sigma-Aldrich®) 1 M 
g.FMR1_CGG_F/R 5 pmol 
Table 5. Asymmetric PCR components.  
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a) Association between CGG repeat number and hormonal levels. 
Principal component analysis was used to arrange the donors in a multi-dimensional 
space defined by the donor’s hormone levels and classified based on the combination of 
repeat number in both alleles, using the Canoco for Windows, version 4.5. 
b) Allelic complexity score values were calculated for both alleles using AGG 
number and pattern breakpoints as:         
  = 
  ×  4


 +  ×  4 
 
Ri: number of CGG repeats before the first AGG interruption of order i (counting from 5’ to 3’) 
n: total number of AGG interspersions. 
Rn+1: number of CGG repeats after the last AGG interruption. 
This mathematical formula simultaneously combines the allele size and the AGG 
interspersion number and pattern. Thus, the allelic score reflects the structure and complexity 
of the AGG interspersion pattern.  
c) Correlation between AGG interspersion number and pattern, the antral 
follicle count and hormonal levels.  
Parametric statistics and multiple linear regression were calculated using Minitab® 
statistical software, version 16 (Minitab® Inc., State College, USA). A significance level of 
0.05 was considered for all the analyses. 
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3. RESULTS & DISCUSSION 
Summary of FMR1 genotyping results in shown in Table 6. Data are divided according 
to the FMR1 sub-genotypes previously defined by others (18). At least one sample was 
identified in each of the six allelic categories. The smallest allele has 15 CGGs and the largest 
48 repeats. As expected, the number of CGG repeats is highly variable with the most frequent 
allele being that with 29 repeats (n=37), followed by alleles with 19 (n=15) and 28 (n=13) 
CGGs (19). In our cohort, eleven homoallelic samples (22%) were identified, of which ten 
belong to the normal group and one to the low/low group (Table 6). One sample belonging 
to the high/high group has one allele in the intermediate range (D50 - annex 1).   Based only 
on allele sizing and on the FMR1 coding DNA Reference Sequence, GenBank 
NM_002024.5, the recommended nomenclature to describe the alleles present in that sample 
is c.-128_-126[40]; [48].  Carriers of intermediate size alleles are excluded from donation, 
as alleles of this size can expand to full mutation in two generations.  
 
 
 
 
 
Alleles CGG repeat number FMR1 sub-genotypes 
classification N 
Homoallelic samples 
(%) 
A1 26<CGG<34 normal 23 44 A2 
A1 8<CGG<25 low/normal 17 0 A2 26<CGG<34 
A1 8<CGG<26 low/high 4 0 A2 35<CGG<55 
A1 26<CGG<34 
normal/high 3 0 A2 35<CGG<55 
A1 8<CGG<26 low/low 2 50 
A2 
A1 34<CGG <55 high/high 1 0 A2 
Table 6. Summary of FMR1 genotyping data in the cohort of 50 potential oocyte donor samples.  
A1- Allele 1 (smallest in size); A2- Allele 2 (largest in size); N – number of samples. 
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*Adapted from (20,21). Values are expressed in mean ± SD. 
  
 All samples presented FSH levels within reference values except for D49. D9 revealed 
elevated prolactin plasma level and D25, D26, D30 and D33, showed estradiol levels above 
normal. Above normal were also the LH levels of D42, D30 and D23. D2, D32 and D25 
disclosed antral follicles below 6, being the last two in the low/normal FMR1 sub-genotype 
and D2 in the normal FMR1 sub-genotype (annex 3).   
 An exploratory approach to identify an association between the CGG number and 
hormonal levels was performed. The six categories of FMR1 sub-genotypes were defined as 
species and each biochemical parameter (FSH, LH, estradiol and prolactin levels) as 
supplementary explanatory variants. The values were centered and standardized within 
Canoco but were not transformed, yielding a biplot correlation. In standardization, all 
variables were considered equally important regardless of their variability.  
 The biplot in Figure 1 depicts the association between samples (grouped according with 
CGG repeat number and corresponding FMR1 sub-genotype) and hormonal levels. The 
distribution of the samples is determined mainly by estradiol (first axis) and prolactin 
(second axis). However, the hormonal profile is not able to separate the groups defined by 
the CGG number. Among the hormones selected for the current study the estradiol alone 
explained 93,2% of the total variance. 
N=50 Reference values* 
Age 25,4 ± 3,9 18-33 years 
Number of antral follicles 8 ± 4,4 > 6 
FSH 5,8 ± 1,7 <10 mIU/mL 
LH 5,9 ± 5,1 <10 mUI/mL 
Estradiol 40,6 ± 24,8 < 60 pg/mL 
Prolactin 14,1 ± 6,4 < 25 ng/mL 
Table 7. Summary of donor characteristics and biochemical data.  
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 Multivariate analysis to project the association between the CGG repeat number and the 
different species, hindered the individualization of the samples classified by FMR1 sub-
genotype. The biplot shows that the hormonal levels are not sufficient to discriminate 
samples according to the FMR1 sub-genotypes which may be due to the large variability of 
the hormonal levels observed among the different samples or to the fact that the CGG repeat 
number and the hormonal levels are independent variables. 
 The absence of an association prompted further investigation of other variables besides 
the length of the CGG tract. Napierala, and co-workers (2005),  have demonstrated that the 
presence of AGG interruptions in the FMR1 repetitive region can influence FXTAS clinical 
outcome in male premutation carriers, by weakening the FMR1 mRNA structure (22). We 
hypothesized that by a similar mechanism, both the length of the CGG tract and the pattern 
Figure 1. Biplot of FMR1 sub-genotypes biochemical results (for 
the 50 potential oocyte donors).   
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of the AGG interspersions, could play a role in the female reproductive function. Thus, a 
mathematical formula was stablished to score FMR1 alleles according to the CGG number 
and AGG number and pattern. The score was named allelic complexity value. Using this 
approach not only the size but also the stability - as determined by the AGG number and 
pattern - were considered. A clear correlation could not be found between the allelic scores 
when they are plotted one against the other (Figure 2).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Allelic complexity score value of each sample. 
Figure 3. Allelic complexity score value based on the allele size and AGG 
interruption number and pattern. Samples carrying alleles of equivalent AGG 
pattern are represented with green lozenges and those with an opposite pattern 
with blue triangles. 
Intermediate-sized allele 
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Nevertheless, when the graph is divided in quadrants cantered at an allelic score of 122 
(Figure 3), two distinct patterns emerge: one where a similar AGG interspersion pattern can 
be observed for both alleles (equivalent group) and a second in which both alleles present 
a different AGG interspersion pattern (opposite group). The equivalent group includes 
samples where both alleles share similar number of AGG interruptions (e.g. one or two). 
Sample D45 containing three AGGs was removed from this analysis (see annex-3 for 
supplementary data). 
 
 
 As shown in Table 8, equivalent group is mainly composed by samples carrying alleles 
in the normal FMR1 sub-genotype. In the opposite group, the most frequent samples show 
an FMR1 low/normal sub-genotype (p=0.027).  
 To strengthen our hypothesis that AGG can influence the ovarian function a correlation 
between the number of antral follicles and the hormonal levels was attained in the equivalent 
group, using Minitab® 16 statistical software.  
 This process was initiated by a stepwise regression performed with all quantified 
hormones. A positive correlation between number of antral follicles, and prolactin and LH 
levels was obtained. A multiple regression for the number of antral folicules using prolactin 
FMR1 sub-genotype N Equivalent group 
 
% 
N 
Opposite group 
 
% 
p 
value 
normal 15 31 8 16 0,0615 
low/normal 5 10 12 25 0,0274 
low/hight 1 2 3 6 --- 
normal/high 1 2 1 2 --- 
low/low 2 4 0 0 --- 
high/high 1 2 0 0 --- 
TOTAL (N=49) 25 51 24 49  
Table 8. Samples distributed according to allelic complexity score groups and FMR1 CGG sub-
genotypes. 
N- number of samples. 
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and LH as descriptors was performed to establish a statistically significant model (p=0.030) 
that predicted the number of antral follicles based on the LH and prolactin levels (Figure 4): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
According to our model, it is possible to determine the largest number of antral 
follicles produced combining the levels of prolactin and LH in the group of females that 
show an equivalent AGG pattern. Interestingly, most of samples of the opposite group carry 
alleles in the low/normal FMR1 sub-genotype (one allele with less than 26 CGGs) (p=0.027). 
This observation is in line with previous publications that suggest a negative influence of a 
tAFC = 3.62+0.523×LH+0.210×PRL 
Figure 4. Isobologram showing the visual representation of the 
mathematical formula. Axes show the LH and Prolactin levels. 
Each color is associated with a specific number of antral 
follicles. A low number of follicles is represented by the blue 
color and the maximum in red. tAFC - Total Antral Follicle 
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low FMR1 CGG number on the ovarian reserve, notwithstanding other elements seem to be 
contributing to this correlation (23).  
In conclusion, the present study shows that the FMR1 CGG repetitive region has an 
impact on the female reproductive function and that AGG interspersions can be used to 
assess the ovarian response success. Our results indicate that in the presence of an equivalent 
AGG pattern, combining the levels of prolactin and LH validly measures the antral follicles 
number. However, this mathematical model, as well as the hypothesis of underlying 
association between FMR1 alleles with CGG<26 with low ovarian reserve and poor ovarian 
response has to be confirmed in future studies. Researchers interested in assessing FMR1 
influence in female ovarian function should consider interpreting the AGG number and 
pattern as one subscale for measuring allelic complexity, beyond allele size. Furthermore, a 
comprehensive evaluation of FMR1 CGG tract impact should be accompanied by the 
assessment of clinical-relevant and female related factors such as the pattern of X-
chromosome inactivation. To establish whether the AGG pattern can determine the ovarian 
response in IVF treatments or oocyte donor selection and be meaningful to changes in 
clinical practice, studies in larger and at-risk cohorts (e.g. infertile couples) are needed.  
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Chapter 3. Discussion and future perspectives 
 
The implication of the FMR1 gene premutation, 55<CGG<200, in the female 
reproductive function has been extensively studied and reported (Man et al., 2017). Still 
under debate is the correlation of the “normal” CGG repeat range with the diminished 
ovarian reserve and other ovarian dysfunction (Bretherick et al., 2005; Bodega et al., 2006; 
Gleicher et al., 2009  and Schufreider et al., 2015; Pastore et al., 2017). 
This controversy led us to test whether an association between a normal number of CGG 
repeats and hormonal levels could be found, in normal and healthy females. A projection of 
the association between the CGG repeat values and the hormonal levels, by multivariate 
analysis, was performed, considering the FMR1 sub-genotypes previously defined. The 
hormonal levels associated with the different samples were not sufficient to discriminate the 
sub-genotypes, indicating that the individualization of the samples classified by sub-
genotype was not possible. An explanation is the large variability of the hormonal levels or 
otherwise, CGG repeat number and the hormone levels are independent. AMH seems to have 
the best discriminatory potential as the basal value remains constant inter- and intra-cycle, 
allowing a reliable evaluation of the ovarian reserve (Gleicher et al., 2015; Pfeifer et al., 
2015; Verissimo and Silvestre, 2016). As AMH has been recently reported as the gold 
standard to predict the ovarian reserve it should be incorporated in future studies. 
AGG interspersions present in the CGG tract have long been considered as stabilizers.  
Their presence in premutated alleles seems to reduce the risk of expansion upon maternal 
transmission (Maia et al., 2016). Thus, we decided to analyze the impact of the AGG number 
and pattern in the ovarian function resorting to a mathematical formula that determines the 
allelic score, taking into account allele size and AGG number and pattern. This allelic score 
reflects the structure and complexity of both alleles of each sample. At an allelic score of 
122, two distinct groups emerged: the equivalent composed mainly of samples carrying 
alleles in the normal FMR1 sub-genotype and the opposite, where most of the samples have 
an FMR1 low/normal sub-genotype (p=0.027). The two groups were individually studied to 
correlate the number of antral follicles and the hormonal levels. In the equivalent group the 
number of antral follicles can be predicted using LH and prolactin levels. The opposite 
group, showing no such correlation, consists mostly of females with one allele above the 
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normal range and another allele below the normal range (low/normal). Interestingly, this 
particular sub-genotype has been associated with a diminished ovarian reserve pattern 
(Gleicher et al., 2015).  
How the stability of the FMR1 alleles can be influencing the ovarian function in females 
is difficult to determine. Another important aspect that needs to be assessed particularly in 
females of the opposite group is the pattern of the X-chromosome inactivation. In the 
presence of a skewed inactivation pattern, the active allele can be contributing differently 
depending on the AGG number and pattern. One can speculate that a less stable allele could 
lead to mRNA accumulation. Then, the resulting toxic effect (either by an RNA gain-of-
function or diminished FMRP synthesis) could cause early follicle atresia and ultimately a 
diminished ovarian reserve/function. Nevertheless, our results highlight the importance of 
the AGG triplets in the ovarian function and suggest that the determination of allele size 
alone, can provide partial results and mislead conclusions. 
Data presented here confirm adverse FMR1 effect in females carrying low CGG repeat 
number and suggest that AGG pattern can be influencing this negative outcome. If further 
studies confirm data reported herein, we suggest that FMR1 testing in oocyte donor 
candidates should include AGG pattern analysis as an additional tool of selection. 
Several weaknesses of this pilot study were drawn in this section.  Possibly the most 
important being the small size of our cohort. On the contrary, the statistical power is 
noteworthy. These results are in line with prior publications and confirm the increasingly 
significant influence of the FMR1 gene on female reproductive function, that can ultimately 
lead to infertility and add the AGG interspersions to the equation of fertility treatments 
success (Kushnir et al., 2014). 
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Annex 1. Summary of data regarding potential oocyte donors.  
 
 
 
PO- Polycystic ovary; NA- Not available 
- 
Samples Age (y) tCAF FSH (mUI/mL)
LH                        
(mUl/mL)
FSH/LH   
(mUl/mL) E2 (pg/mL) PRL (ng/mL) A1 A2
D01 20 10 5,4 4,8 1,1 39,9 4,0 28 29
D02 30 5 6,2 5,4 1,1 55,5 24,2 29 29
D03 30 10 5,0 6,7 0,7 57,7 13,6 29 29
D04 22 7 6,3 5,6 1,1 15,8 5,0 28 29
D05 28 12 8,9 6,5 1,4 51,5 9,8 29 34
D06 28 9 5,2 5,2 1,0 33,7 10,3 29 31
D07 19 8 4,7 3,4 1,4 37,1 9,1 29 32
D08 25 9 7,0 4,5 1,6 70,2 7,3 29 29
D09 28 PO 3,2 5,0 0,6 24,0 15,0 29 29
D10 29 9 5,8 3,2 1,8 37,4 11,6 29 30
D11 31 7 5,5 2,7 2,0 54,9 16,5 29 29
D12 18 10 5,3 3,0 1,8 14,8 20,0 29 32
D13 28 10 7,0 4,6 1,5 61,8 17,7 28 29
D14 33 6 6,5 3,4 1,9 33,5 23,5 28 30
D15 21 9 5,6 2,7 2,1 35,5 10,5 29 29
D16 21 11 5,7 2,7 2,1 37,9 25,7 29 29
D17 29 PO 4,9 3,9 1,3 46,5 6,9 29 29
D18 22 11 4,1 4,3 1,0 25,9 16,3 29 29
D19 23 PO 4,1 3,7 1,1 25,7 19,0 28 29
D20 30 6 7,1 4,7 1,5 36,5 7,6 29 31
D21 26 7 6,7 6,6 1,0 50,4 10,0 28 28
D22 21 PO 5,9 5,9 1,0 36,2 10,6 29 30
D23 25 10 3,7 38,0 0,1 26,8 8,7 28 30
D24 23 16 4,9 8,5 0,6 26,4 30,9 24 30
D25 23 4 3,1 2,4 1,3 83,5 9,1 22 29
D26 26 PO 3,7 6,9 0,5 81,6 26,2 19 29
D27 24 6 6,2 3,6 1,7 25,3 11,4 19 30
D28 25 NA 5,7 3,0 1,9 33,4 11,6 19 29
D29 28 12 5,7 2,9 2,0 45,6 17,7 20 28
D30 28 9 9,5 10,6 0,9 148,0 20,7 19 31
D31 30 11 6,3 7,4 0,9 56,6 23,4 19 28
D32 31 5 4,8 5,8 0,8 5,0 7,3 19 28
D33 28 11 5,2 6,7 0,8 81,2 14,1 17 32
D34 26 9 6,7 6,3 1,1 23,0 9,8 23 28
D35 22 7 6,0 8,8 0,7 35,9 7,6 15 29
D36 22 12 6,8 5,2 1,3 22,5 11,7 19 29
D37 23 12 9,5 9,3 1,0 54,7 19,8 19 29
D38 18 16 5,7 5,8 1,0 26,7 18,3 24 30
D39 23 PO 2,8 1,7 1,6 13,2 6,8 19 31
D40 31 10 4,5 3,9 1,2 19,5 NA 17 29
D41 26 10 4,6 3,3 1,4 36,0 10,6 19 37
D42 20 PO 7,6 11,7 0,6 42,9 13,9 22 36
D43 25 6 4,3 5,3 0,8 10,6 13,1 19 37
D44 27 15 7,3 5,4 1,4 60,7 10,8 19 35
D45 22 12 6,4 6,3 1,0 10,7 16,4 29 38
D46 23 10 3,3 2,6 1,3 69,4 10,4 28 38
D47 31 9 5,1 4,5 1,1 5,0 17,8 31 38
D48 21 13 6,7 3,4 2,0 54,2 21,9 19 19
D49 31 10 11,1 8,0 1,4 30,6 11,0 19 22
D50 26 PO 7,0 9,7 0,7 16,5 13,7 40 48
Allele  Size (bp)l le size 
(CGG 
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Annex 2. Results of AGG interrution patterns.  
 
a) A of cases studied by TP-PCR (n=45): 
 
 
1. Sample D08. 
 
 
 
 
 
 
 
AGG interruption pattern:  
Allele 1 - [CGG]9AGG[CGG]9AGG[CGG]9 
Allele 2 - [CGG]9AGG[CGG]9AGG[CGG]9 
 
2. Sample D43. 
 
 
 
AGG interruption pattern:  
Allele 1 - [CGG]10AGG[CGG]8  
Allele 2 - [CGG]8AGG[CGG]6AGG[CGG]9AGG[CGG]9 
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b) Exemples of cases studied by TP-PCR and RFLA (n=4): 
 
 
1. Sample D02 
 
 
 
 
 
 
 
 
AGG interruption pattern:  
Allele 1 - [CGG]29 or [CGG]19AGG[CGG]9 
Allele 2 - [CGG]9AGG[CGG]9AGG[CGG]9 or [CGG]9AGG[CGG]19 
 
 
 
2. Sample D24. 
 
 
 
 
 
 
AGG interruption pattern:  
Allele 1 - [CGG]24 or [CGG]14AGG[CGG]9 
Allele 2 - [CGG]10AGG[CGG]9AGG[CGG]9 or [CGG]10AGG[CGG]19 
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3. Sample D18. 
 
 
 
 
 
 
 
AGG interruption pattern:  
Allele 1 - [CGG]29 or [CGG]19AGG[CGG]9 
Allele 2 - [CGG]9AGG[CGG]9AGG[CGG]9 or [CGG]9AGG[CGG]19 
 
 
 
4. Sample D35. 
 
 
 
 
 
 
 
 
 
AGG interruption pattern: 
Allele 1 - [CGG]15 or [CGG]5AGG[CGG]9  
Allele 2 - [CGG]9AGG[CGG]9AGG[CGG]9 or [CGG]9AGG[CGG]19 
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5. Size of the expected fragment if the smallest allele is pure.  
 
 
 
 
 
 
 
 
c) Example of cases studied by TP-PCR (in-house and commercial methods) 
(n=1):  
 
1. Sample D37. 
 
 
 
 
 
 
 
  
 
 
 
*If the smallest allele is pure 
Image adapted from the simulator NEBcutter®. 
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AGG interruption pattern: 
Allele 1 – [CGG]9AGG[CGG]9 or [CGG]19  
Allele 2 - [CGG]9AGG[CGG]19 or [CGG]9AGG[CGG]9AGG[CGG]9 
 
2. Sample D37. 
 
 
 
 
 
 
 
 
 
 
 
d) Case studied by TP-PCR and Sanger Sequencing (n=1): 
 
1. Sample D33. 
 
 
 
 
 
 
 
 
AGG interruption pattern: 
Allele 1 - [CGG]9AGG[CGG]7 or [CGG]17  
Allele 2 - [CGG]8AGG[CGG]23 or [CGG]8AGG[CGG]15AGG[CGG]7 
FRAXA PCR kit (LabSscanTM) 
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2. Sample D33.  
 
Partied electropherogram of Sample D33. 
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Annex 3. Summary of data organized according AGG interruption pattern and allelic score. 
   
            Allele Size 
AGG interspersion pattern  
TP-PCR; Sanger sequencing; RFLA; TP-PCR (commercial kit) 
E
q
u
iv
a
le
n
t 
p
a
tt
e
r
n
 g
r
o
u
p
 
Samples Age 
(y) 
tAFC FSH             
(mUl/ml) 
LH                        
(mUl/ml) 
E2 
(pg/ml) 
PRL 
(ng/ml) 
A1 A2 Allele 1 Allele 2 
D48 21 13 6,7 3,4 54,2 21,9 19 19 [CGG]9AGG[CGG]9 [CGG]9AGG[CGG]9 
D49 31 10 11,1 8,0 30,6 11,0 19 22 [CGG9AGG[CGG]9 [CGG]9AGG[CGG]12 
D33 28 11 5,2 6,7 81,2 14,1 17 32 [CGG]9AGG[CGG]7  [CGG]8AGG[CGG]23  
D37 23 12 9,5 9,3 54,7 19,8 19 29 [CGG]9AGG[CGG]9 [CGG]9AGG[CGG]19 
D29 28 12 5,7 2,9 45,6 17,7 20 28 [CGG]10AGG[CGG]9 [CGG]16AGG[CGG]11 
D25 23 4 3,1 2,4 83,5 9,1 22 29 [CGG]12AGG[CGG]9 [CGG]16AGG[CGG]12 
D34 26 9 6,7 6,3 23,0 9,8 23 28 [CGG]15AGG[CGG]8 [CGG]18AGG[CGG]9 
D42 20 PO 7,6 11,7 42,9 13,9 22 36 [CGG]13AGG[CGG]8 [CGG]24AGG[CGG]11 
D21 26 7 6,7 6,6 50,4 10,0 28 28 [CGG]9AGG[CGG]9AGG[CGG]8 [CGG]9AGG[CGG]9AGG[CGG]8 
D13 28 10 7,0 4,6 61,8 17,7 28 29 [CGG]9AGG[CGG]9AGG[CGG]8 [CGG]9AGG[CGG]9AGG[CGG]9 
D19 23 0P 4,1 3,7 25,7 19,0 28 29 [CGG]9AGG[CGG]9AGG[CGG]8 [CGG]9AGG[CGG]9AGG[CGG]9 
D03 30 10 5,0 6,7 57,7 13,6 29 29 [CGG]9AGG[CGG]9AGG[CGG]9 [CGG]9AGG[CGG]9AGG[CGG]9 
D08 25 9 7,0 4,5 70,2 7,3 29 29 [CGG]9AGG[CGG]9AGG[CGG]9 [CGG]9AGG[CGG]9AGG[CGG]9 
D09 28 PO 3,2 5,0 24,0 15,0 29 29 [CGG]9AGG[CGG]9AGG[CGG]9 [CGG]9AGG[CGG]9AGG[CGG]9 
D11 31 7 5,5 2,7 54,9 16,5 29 29 [CGG]9AGG[CGG]9AGG[CGG]9 [CGG]9AGG[CGG]9AGG[CGG]9 
D15 21 9 5,6 2,7 35,5 10,5 29 29 [CGG]9AGG[CGG]9AGG[CGG]9 [CGG]9AGG[CGG]9AGG[CGG]9 
D16 21 11 5,7 2,7 37,9 25,7 29 29 [CGG]9AGG[CGG]9AGG[CGG]9 [CGG]9AGG[CGG]9AGG[CGG]9 
D17 29 PO 4,9 3,9 46,5 6,9 29 29 [CGG]9AGG[CGG]9AGG[CGG]9 [CGG]9AGG[CGG]9AGG[CGG]9 
D06 28 9 5,2 5,2 33,7 10,3 29 31 [CGG]9AGG[CGG]10AGG[CGG]8 [CGG]9AGG[CGG]11AGG[CGG]9 
D20 30 6 7,1 4,7 36,5 7,6 29 31 [CGG]9AGG[CGG]10AGG[CGG]8 [CGG]9AGG[CGG]11AGG[CGG]9 
D04 22 7 6,3 5,6 15,8 5,0 28 29 [CGG]9AGG[CGG]9AGG[CGG]8 [CGG]10AGG[CGG]9AGG[CGG]8 
D14 33 6 6,5 3,4 33,5 23,5 28 30 [CGG]9AGG[CGG]9AGG[CGG]8 [CGG]10AGG[CGG]9AGG[CGG]9 
D05 28 12 8,9 6,5 51,5 9,8 29 34 [CGG]9AGG[CGG]10AGG[CGG]8 [CGG]14AGG[CGG]9AGG[CGG]9 
D47 31 9 5,1 4,5 5,0 17,8 31 38 [CGG]12AGG[CGG]9AGG[CGG]8 [CGG]18AGG[CGG]9AGG[CGG]9 
(D45) 22 12 6,4 6,3 10,7 16,4 29 38 [CGG]10AGG[CGG]9AGG[CGG]8 CGG]8AGG[CGG]9AGG[CGG]9AGG[CGG]9 
D50 26 PO 7,0 9,7 16,5 13,7 40 48 [CGG]22AGG[CGG]9AGG[CGG]7 [CGG]30AGG[CGG]8AGG[CGG8 
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D35 22 7 6,0 8,8 35,9 7,6 15 29 [CGG]15  [CGG]9AGG[CGG]9AGG[CGG]9  
D02 30 5 6,2 5,4 55,5 24,2 29 29 [CGG]29 [CGG]9AGG[CGG]9AGG[CGG]9 
D18 22 11 4,1 4,3 25,9 16,3 29 29 [CGG]29 [CGG]9AGG[CGG]9AGG[CGG]9 
D24 23 16 4,9 8,5 26,4 30,9 24 30 [CGG]24  [CGG]10AGG[CGG]9AGG[CGG]9 
D26 26 PO 3,7 6,9 81,6 26,2 19 29 [CGG]9AGG[CGG]9 [CGG]9AGG[CGG]9AGG[CGG]9 
D28 25 NA 5,7 3,0 33,4 11,6 19 29 [CGG]9AGG[CGG]9 [CGG]9AGG[CGG]9AGG[CGG]9 
D40 31 10 4,5 3,9 19,5 NA 17 29 [CGG]10AGG[CGG]6 [CGG]9AGG[CGG]9AGG[CGG]9  
D36 22 12 6,8 5,2 22,5 11,7 19 29 [CGG]10AGG[CGG]8 [CGG]9AGG[CGG]9AGG[CGG]9 
D39 23 PO 2,8 1,7 13,2 6,8 19 31 [CGG]10AGG[CGG]8 [CGG]9AGG[CGG]12AGG[CGG]8 
D27 24 6 6,2 3,6 25,3 11,4 19 30 [CGG]9AGG[CGG]9 [CGG]10AGG[CGG]9AGG[CGG]9 
D01 20 10 5,4 4,8 39,9 4,0 28 29 [CGG]9AGG[CGG]9AGG[CGG]8 [CGG]9AGG[CGG]9AGG[CGG]9 
D30 28 9 9,5 10,6 148,0 20,7 19 31 [CGG]9AGG[CGG]9 [CGG]10AGG[CGG]10AGG[CGG]9 
D38 18 16 5,7 5,8 26,7 18,3 24 30 [CGG]9AGG[CGG]14 [CGG]10AGG[CGG]9AGG[CGG]9 
D31 30 11 6,3 7,4 56,6 23,4 19 28 [CGG]10AGG[CGG]8 [CGG]8AGG[CGG]9AGG[CGG]9 
D32 31 5 4,8 5,8 5,0 7,3 19 28 [CGG]10AGG[CGG]8 [CGG]8AGG[CGG]9AGG[CGG]9 
D23 25 10 3,7 38,0 26,8 8,7 28 30 [CGG]9AGG[CGG]9AGG[CGG]8  [CGG]19AGG[CGG]10  
D10 29 9 5,8 3,2 37,4 11,6 29 30 [CGG]9AGG[CGG]9AGG[CGG]9  [CGG]20AGG[CGG]9  
D22 21 PO 5,9 5,9 36,2 10,6 29 30 [CGG]9AGG[CGG]9AGG[CGG]9  [CGG]20AGG[CGG]9  
D07 19 8 4,7 3,4 37,1 9,1 29 32 [CGG]9AGG[CGG]9AGG[CGG]9  [CGG]22AGG[CGG]9  
D12 18 10 5,3 3,0 14,8 20,0 29 32 [CGG]9AGG[CGG]9AGG[CGG]9  [CGG]22AGG[CGG]9  
D46 23 10 3,3 2,6 69,4 10,4 28 38 [CGG]9AGG[CGG]9AGG[CGG]8  [CGG]29AGG[CGG]8  
D44 27 15 7,3 5,4 60,7 10,8 19 35 [CGG]10AGG[CGG]8 [CGG]8AGG[CGG]6AGG[CGG]9AGG[CGG]9 
D43 25 6 4,3 5,3 10,6 13,1 19 37 [CGG]9AGG[CGG]9 [CGG]8AGG[CGG]8AGG[CGG]9AGG[CGG]9  
D41 26 10 4,6 3,3 36,0 10,6 19 37 [CGG]10AGG[CGG]8 [CGG]8AGG[CGG]8AGG[CGG]9AGG[CGG]9  
PO - Polycystic Ovary; NA- Not Available; (D45) - sample removed from statistical study; normal/normal; normal/low; low/high; normal/high; low/low; high/high. 
  
 
